CD8A and hepatocellular carcinoma: The HCC TMA cohort indicated that those with dual-positive VISTA and CD8 showed a significantly longer OS than other subsets (VISTA+/CD8+ vs VISTA+/CD8- vs VISTA-/CD8+ vs VISTA-/CD8-: 74 vs 27 vs 57 vs 35 months, p = 0.023) subtypes (Fig. 3c).